美国Proteon Therapeutics
Proteon Therapeutics, Inc is a privately held biopharmaceutical company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with renal and vascular diseases. The company is leveraging a unique understanding of tissue remodeling to develop a pipeline of proprietary therapeutics. Proteon Therapeutics’ first drug candidate (PRT-201) is in development for the improvement of blood flow following vascular surgery procedures. The Company’s initial clinical focus is vascular access for hemodialysis and peripheral arterial disease (PAD).